ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Tobacco Regulation: ACS Advocates Giving FDA Full Authority Over Tobacco

January 23, 1998

Organ Site Report On Pancreas Project, Breast cancer TF

May 7, 1976

Six Centers Win Grants

July 11, 2003

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003

How Cancer Control Grants, Contracts Distributed By States

October 13, 1978

NCI Advisory Group Meetings for July

June 27, 1975